Search bioRxiv⌕ Search

Biology subjects

Simonet, C.

Publications and source records attributed to Simonet, C..

2 recordsLinked to original sources

Sex decreases the pleiotropic costs of local adaptation

Understanding the evolutionary mechanisms that maintain sex throughout nature despite its substantial direct costs is a longstanding challenge in biology. Previous work has shown that sexual recombination provides a key advantage in speeding adaptation, in part by separating beneficial mutations from deleterious hitchhikers. However, these earlier studies have focused on the effects of sex in a constant environment. Here, we show that recombination also provides a key advantage in fluctuating conditions, promoting the evolution of generalist phenotypes by reducing the pleiotropic costs of local adaptation. Using laboratory evolution in S. cerevisiae as a model system, we show that hitchhiking genetic load leads to pleiotropic costs and hence specialization in response to local adaptation in asexual but not in sexual lineages. This provides the first direct evidence that sex can be maintained over longer evolutionary timescales because it enables lineages to persist in the face of environmental change.

evolutionary biology↗

Focussing on resistance to front-line drugs is the most effective way to combat the antimicrobial resistance crisis

In medical, scientific and political arenas relating to antimicrobial resistance (AMR) there is currently an intense focus on multi-drug resistant pathogens that render last-line antimicrobial treatments ineffective. We question the current emphasis of attention on resistance to last-line antimicrobials, arguing that tackling resistance to front-line antimicrobials has a greater public health benefit. Using AMR monitoring data on 25 drug-pathogen combinations from across Europe, here we show that the presence of front-line pathogen resistance initiates a cascade of resistance selection that ultimately leads to pathogen resistance to last-line antimicrobials. We then interrogate, by modelling the dynamics of resistance evolution, whether 3 key interventions in the strategic response to AMR are more effectively targeted at front-line or last-line treatment. We show that interventions that make front-line therapy more effective by use of antimicrobial adjuvants or front-line resistance diagnostics or by introduction of a novel, front-line antimicrobial all lead to a larger reduction in mortality and morbidity than the same interventions implemented in last-line therapy. Mass use of a newly discovered antimicrobial in front-line infection management to maximise its public health benefit is contrary to current policy but may provide valuable incentives for drug developers. We demonstrate that funding, publications, and attention to those publications do not reflect the importance of front-line antimicrobials and are disproportionately devoted to last-line antimicrobials that account for less than 10% of antimicrobial prescriptions. While studying resistance to last-line drugs is undoubtedly important, our work relays a strong message to public health agencies, funding bodies, and researchers that allocating resources to front-line infections can be a more effective way to combat the antimicrobial resistance crisis.

evolutionary biology↗